^
Association details:
| Biomarker: | MLL translocation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia
Published date:
11/06/2019
Excerpt:
Certain cytogenetic features correlated with greater sensitivity to Rux+Ven (e.g. t(9;11) - MLL-rearrangement) or decreased sensitivity (e.g. t(15;17) - PML-RARA or monosomy 5/del 5q) (Fig. 1B).
DOI:
https://doi.org/10.1182/blood-2019-126020
